• Avaxia leads the field
    of gut-targeted
    antibody therapeutics

Our Company

Avaxia is a clinical-stage biotechnology company focused on the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. Our drugs are gut-targeted antibodies. Traditional antibody therapeutics are injected or infused into the bloodstream and distribute throughout the body. In contrast, Avaxia antibody therapeutics are taken orally and are intended to remain in the GI tract. Our gut-targeted antibodies open an entirely new market opportunity for antibody therapeutics.


AVX-470, our first gut-targeted antibody therapeutic, is currently in clinical development for inflammatory bowel disease (IBD). The antibody binds TNF, an inflammatory protein. Marketed anti-TNF drugs, such as Remicade® (infliximab), have proven to be highly effective for the treatment of IBD, including ulcerative colitis and Crohn’s disease. However, these anti-TNF drugs have rare but serious side effects, such as risk of serious infection, because they dampen the immune system throughout the body. AVX-470 is intended to act only locally in the intestines where the disease occurs, potentially treating IBD without these rare but serious side effects.